ASKB589 + capecitabine + oxaliplatin + sintilimab

ASKB589 + capecitabine + oxaliplatin + sintilimab is a combination therapy under investigation for the treatment of advanced or metastatic gastric and gastroesophageal junction cancers. ASKB589 is a humanized IgG1 monoclonal antibody targeting Claudin 18.2 (CLDN18.2), a tight junction protein highly expressed in certain tumors but limited in normal tissues, mediating antitumor effects via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity[1][3][5]. Capecitabine is an oral prodrug of 5-fluorouracil, while oxaliplatin is a platinum-based chemotherapeutic; together they form the CAPOX regimen, which disrupts DNA synthesis and function[6][8]. Sintilimab is an anti-PD-1 monoclonal antibody that enhances immune-mediated tumor cell killing. This combination has shown promising efficacy and safety in early-phase clinical trials for patients with CLDN18.2-positive gastric or gastroesophageal junction cancers[7].

Brand names

Xeloda (for capecitabine)Tyvyt (for sintilimab)

Other names

XELOX (for CAPOX regimen)